Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Emma Allen-Vercoe
Queen's University at Kingston, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nubiyota LLC ("Company")
Other : Minor shareholder ((b)(4)) in Company; Chief Scientific Officer; milestone payment received from Company. The value of the shares cannot be readily determined through reference to public prices or other reasonable measures of fair market value. The amount of the milestone payment received from Company is (b)(4)
Company was founded to develop results and findings of research conducted by Investigator and (b)(6) in the field of microbial ecosystem therapeutics. Investigator's involvement in research sponsored by Company, pertaining to the field of microbial ecosystem therapeutics, or pertaining to intellectual property owned by or licensed to Company in which she holds an interest or is entitled to receive revenue ("MET Research") may raise questions of her objectivity in conducting such research. The Project pertains to the field of microbial ecosystem therapeutics.
Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics
C. difficile infection (CDI) causes 14,000 deaths a year, and over $1 billion is spent on the extended hospitalization and treatment of complications related to CDI. Clostridium difficile is considered an 'urgent threat' pathogen by the CDC and new, more effective treatments are urgently needed. Using a novel approach that is fundamentally different from antibiotics and from existing stool transplant approaches to treat CDI, this application proposes to develop defined bacterial communities as therapeutics to treat CDI, using novel strategies of rational design based on microbial ecosystem function.
Filed on November 26, 2018.
Tell us what you know about Emma Allen-Vercoe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Emma Allen-Vercoe filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Emma Allen-Vercoe | Queen's University at Kingston | Conflict of Interest | University of Guelph | Value cannot be readily determined |
| Emma Allen-Vercoe | Queen's University at Kingston | Conflict of Interest | University of Guelph | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.